581 related articles for article (PubMed ID: 15374980)
1. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Wood ER; Truesdale AT; McDonald OB; Yuan D; Hassell A; Dickerson SH; Ellis B; Pennisi C; Horne E; Lackey K; Alligood KJ; Rusnak DW; Gilmer TM; Shewchuk L
Cancer Res; 2004 Sep; 64(18):6652-9. PubMed ID: 15374980
[TBL] [Abstract][Full Text] [Related]
2. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
3. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.
Stamos J; Sliwkowski MX; Eigenbrot C
J Biol Chem; 2002 Nov; 277(48):46265-72. PubMed ID: 12196540
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain.
Park JH; Liu Y; Lemmon MA; Radhakrishnan R
Biochem J; 2012 Dec; 448(3):417-23. PubMed ID: 23101586
[TBL] [Abstract][Full Text] [Related]
5. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.
Lackey KE
Curr Top Med Chem; 2006; 6(5):435-60. PubMed ID: 16719802
[TBL] [Abstract][Full Text] [Related]
6. Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines.
Bridges AJ; Cody DR; Zhou H; McMichael A; Fry DW
Bioorg Med Chem; 1995 Dec; 3(12):1651-6. PubMed ID: 8770389
[TBL] [Abstract][Full Text] [Related]
7. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
Rusnak DW; Alligood KJ; Mullin RJ; Spehar GM; Arenas-Elliott C; Martin AM; Degenhardt Y; Rudolph SK; Haws TF; Hudson-Curtis BL; Gilmer TM
Cell Prolif; 2007 Aug; 40(4):580-94. PubMed ID: 17635524
[TBL] [Abstract][Full Text] [Related]
8. Treatment of vestibular schwannoma cells with ErbB inhibitors.
Bush ML; Burns SS; Oblinger J; Davletova S; Chang LS; Welling DB; Jacob A
Otol Neurotol; 2012 Feb; 33(2):244-57. PubMed ID: 22222570
[TBL] [Abstract][Full Text] [Related]
9. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Konecny GE; Pegram MD; Venkatesan N; Finn R; Yang G; Rahmeh M; Untch M; Rusnak DW; Spehar G; Mullin RJ; Keith BR; Gilmer TM; Berger M; Podratz KC; Slamon DJ
Cancer Res; 2006 Feb; 66(3):1630-9. PubMed ID: 16452222
[TBL] [Abstract][Full Text] [Related]
10. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.
Arteaga CL; Ramsey TT; Shawver LK; Guyer CA
J Biol Chem; 1997 Sep; 272(37):23247-54. PubMed ID: 9287333
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
[TBL] [Abstract][Full Text] [Related]
12. Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.
Bhattacharya SK; Cox ED; Kath JC; Mathiowetz AM; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Richter DT; Su C; Wessel MD
Biochem Biophys Res Commun; 2003 Jul; 307(2):267-73. PubMed ID: 12859950
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.
Okamura T; Singh S; Buolamwini J; Haystead T; Friedman H; Bigner D; Ali-Osman F
J Biol Chem; 2009 Jun; 284(25):16979-16989. PubMed ID: 19254954
[TBL] [Abstract][Full Text] [Related]
15. In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.
Qiu C; Tarrant MK; Boronina T; Longo PA; Kavran JM; Cole RN; Cole PA; Leahy DJ
Biochemistry; 2009 Jul; 48(28):6624-32. PubMed ID: 19518076
[TBL] [Abstract][Full Text] [Related]
16. Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors.
Macdonald-Obermann JL; Pike LJ
J Biol Chem; 2018 Aug; 293(35):13401-13414. PubMed ID: 29997256
[TBL] [Abstract][Full Text] [Related]
17. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
19. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
Fry DW; Bridges AJ; Denny WA; Doherty A; Greis KD; Hicks JL; Hook KE; Keller PR; Leopold WR; Loo JA; McNamara DJ; Nelson JM; Sherwood V; Smaill JB; Trumpp-Kallmeyer S; Dobrusin EM
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):12022-7. PubMed ID: 9751783
[TBL] [Abstract][Full Text] [Related]
20. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
